Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced the presentation of two posters at the virtual 16th International Congress on Neuromuscular Diseases on May 21-22 and 28-29, 2021. The posters focus on its development program for Pompe disease, including:

• Enhancing Delivery of Acid Alpha-Glucosidase to Skeletal Muscle by Nithya Selvan, Ph.D.
• Efficacy and Safety of Cipaglucosidase Alfa/Miglustat versus Alglucosidase Alfa/Placebo in Late-Onset Pompe Disease presented by Benedikt Schoser, MD.

The posters will be available on the Amicus website after the presentations.

PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases (ICNMD) being held virtually, May 21-22 and 28-29, 2021.

ePoster Presentations:

• Enhancing Delivery of Acid Alpha-Glucosidase to Skeletal Muscle in Pompe Disease: Key Challenges and Attributes of AT-GAA
  • Presenter: Nithya Selvan, Ph.D., Amicus Therapeutics, Philadelphia, PA, USA

• Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study
  • Presenter: Benedikt Schoser, MD, Department of Neurology, Ludwig-Maximilians-University of Munich, Germany

The posters will be made available on the Amicus website following their respective presentations at the congress.

For more information on the 16^th International Congress on Neuromuscular Diseases, please visit www.icnmd.org.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:
Andrew Faughnan
Sr. Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

 

FAQ

What did Amicus Therapeutics present at the ICNMD 2021?

Amicus Therapeutics presented two posters on its Pompe disease development program at the 16th International Congress on Neuromuscular Diseases.

When is the 16th International Congress on Neuromuscular Diseases?

The congress is held virtually on May 21-22 and 28-29, 2021.

Who presented on the efficacy of cipaglucosidase alfa in Pompe disease?

Benedikt Schoser, MD, presented the poster on the efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo.

Where can I find the posters presented by Amicus Therapeutics?

The posters will be available on the Amicus Therapeutics website following their respective presentations.

What is the significance of AT-GAA in Pompe disease treatment?

The poster discusses key challenges and attributes of enhancing delivery of Acid Alpha-Glucosidase to skeletal muscle in Pompe disease.